{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:04:07Z","timestamp":1791317047363,"version":"4.3.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["New Biotechnology"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.nbt.2013.01.005","type":"journal-article","created":{"date-parts":[[2013,1,28]],"date-time":"2013-01-28T15:31:30Z","timestamp":1359387090000},"page":"299-301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Advances in therapeutic RNA-targeting"],"prefix":"10.1016","volume":"30","author":[{"given":"Gert-Jan B.","family":"van Ommen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Aartsma-Rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"October (10)","key":"10.1016\/j.nbt.2013.01.005_bib0005","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nrg1180","article-title":"Advances in Duchenne muscular dystrophy gene therapy","volume":"4","author":"van Deutekom","year":"2003","journal-title":"Nature Reviews Genetics"},{"issue":"March (6)","key":"10.1016\/j.nbt.2013.01.005_bib0010","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.cell.2012.02.014","article-title":"Splice modulating therapies for human disease","volume":"148","author":"Spitali","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.nbt.2013.01.005_bib0015","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(02)07815-7","article-title":"The muscular dystrophies","volume":"359","author":"Emery","year":"2002","journal-title":"Lancet"},{"issue":"December (6)","key":"10.1016\/j.nbt.2013.01.005_bib0020","first-page":"835","article-title":"Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications","volume":"45","author":"Den Dunnen","year":"1989","journal-title":"American Journal of Human Genetics"},{"issue":"August (2)","key":"10.1016\/j.nbt.2013.01.005_bib0025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1086\/341942","article-title":"Comprehensive detection of genomic duplications and deletions in the DMD gene, by use of multiplex amplifiable probe hybridization","volume":"71","author":"White","year":"2002","journal-title":"American Journal of Human Genetics"},{"key":"10.1016\/j.nbt.2013.01.005_bib0030","first-page":"22","article-title":"Spectrum of small mutations in the dystrophin coding region","volume":"57","author":"Prior","year":"1995","journal-title":"American Journal of Human Genetics"},{"issue":"1","key":"10.1016\/j.nbt.2013.01.005_bib0035","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","article-title":"An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus","volume":"2","author":"Monaco","year":"1988","journal-title":"Genomics"},{"issue":"July (7)","key":"10.1016\/j.nbt.2013.01.005_bib0040","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/hmg\/7.7.1083","article-title":"Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides","volume":"7","author":"Dunckley","year":"1998","journal-title":"Human Molecular Genetics"},{"issue":"July (15)","key":"10.1016\/j.nbt.2013.01.005_bib0045","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/hmg\/10.15.1547","article-title":"Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells","volume":"10","author":"van Deutekom","year":"2001","journal-title":"Human Molecular Genetics"},{"issue":"April (8)","key":"10.1016\/j.nbt.2013.01.005_bib0050","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/hmg\/ddg100","article-title":"Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients","volume":"12","author":"Aartsma-Rus","year":"2003","journal-title":"Human Molecular Genetics"},{"issue":"January (1)","key":"10.1016\/j.nbt.2013.01.005_bib0055","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1073\/pnas.98.1.42","article-title":"Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse","volume":"98","author":"Mann","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"August (8)","key":"10.1016\/j.nbt.2013.01.005_bib0060","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nm897","article-title":"Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse","volume":"9","author":"Lu","year":"2003","journal-title":"Nature Medicine"},{"issue":"August (2)","key":"10.1016\/j.nbt.2013.01.005_bib0065","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ymthe.2004.05.031","article-title":"Targeted exon skipping in transgenic hDMD mice: a model for direct preclinical screening of human-specific antisense oligonucleotides","volume":"10","author":"Bremmer-Bout","year":"2004","journal-title":"Molecular Therapy"},{"issue":"January (1)","key":"10.1016\/j.nbt.2013.01.005_bib0070","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1073\/pnas.0406700102","article-title":"Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles","volume":"102","author":"Lu","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"December (26)","key":"10.1016\/j.nbt.2013.01.005_bib0075","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1056\/NEJMoa073108","article-title":"Local dystrophin restoration with antisense oligonucleotide PRO051","volume":"357","author":"van Deutekom","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"October (10)","key":"10.1016\/j.nbt.2013.01.005_bib0080","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","article-title":"Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study","volume":"8","author":"Kinali","year":"2009","journal-title":"Lancet Neurology"},{"issue":"April (16)","key":"10.1016\/j.nbt.2013.01.005_bib0085","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1011367","article-title":"Systemic administration of PRO051 in Duchenne's muscular dystrophy","volume":"364","author":"Goemans","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"August (9791)","key":"10.1016\/j.nbt.2013.01.005_bib0090","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"issue":"July (8970)","key":"10.1016\/j.nbt.2013.01.005_bib0095","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0140-6736(95)92206-7","article-title":"SMN gene deletion in variant of infantile spinal muscular atrophy","volume":"346","author":"B\u00fcrglen","year":"1995","journal-title":"Lancet"},{"issue":"November (11)","key":"10.1016\/j.nbt.2013.01.005_bib0100","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.nmd.2005.07.005","volume":"15","author":"Bertini","year":"2005","journal-title":"Neuromuscular Disorders"},{"issue":"April (4)","key":"10.1016\/j.nbt.2013.01.005_bib0105","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pbio.0050073","article-title":"Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon","volume":"5","author":"Hua","year":"2007","journal-title":"PLoS Biology"},{"issue":"April (4)","key":"10.1016\/j.nbt.2013.01.005_bib0110","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice","volume":"82","author":"Hua","year":"2008","journal-title":"American Journal of Human Genetics"},{"issue":"August (15)","key":"10.1016\/j.nbt.2013.01.005_bib0115","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes and Development"},{"issue":"October (7367)","key":"10.1016\/j.nbt.2013.01.005_bib0120","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"issue":"October (106)","key":"10.1016\/j.nbt.2013.01.005_bib0125","first-page":"106","article-title":"Splicing-directed therapy in a new mouse model of human accelerated aging","volume":"3","author":"Osorio","year":"2011","journal-title":"Science Translational Medicine"},{"issue":"August (2)","key":"10.1016\/j.nbt.2013.01.005_bib0130","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1124\/mol.58.2.380","article-title":"Deletion of individual exons and induction of soluble murine interleukin-5 receptor-alpha chain expression through antisense oligonucleotide-mediated redirection of pre-mRNA splicing","volume":"58","author":"Karras","year":"2000","journal-title":"Molecular Pharmacology"},{"issue":"April (Suppl. 2)","key":"10.1016\/j.nbt.2013.01.005_bib0135","doi-asserted-by":"crossref","first-page":"i75","DOI":"10.1136\/annrheumdis-2011-200971","article-title":"Antisense oligonucleotide mediated exon skipping as a potential strategy for the treatment of a variety of inflammatory diseases such as rheumatoid arthritis","volume":"71","author":"Yilmaz-Elis","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"October (43)","key":"10.1016\/j.nbt.2013.01.005_bib0140","doi-asserted-by":"crossref","first-page":"17779","DOI":"10.1073\/pnas.1108482108","article-title":"Antitumorigenic potential of STAT3 alternative splicing modulation","volume":"108","author":"Zammarchi","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"April (4)","key":"10.1016\/j.nbt.2013.01.005_bib0145","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1096\/fj.11-191189","article-title":"Cell-type specific regulation of myostatin signaling","volume":"26","author":"Kemaladewi","year":"2012","journal-title":"FASEB Journal"},{"issue":"April","key":"10.1016\/j.nbt.2013.01.005_bib0150","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1755-8794-4-36","article-title":"Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy","volume":"4","author":"Kemaladewi","year":"2011","journal-title":"BMC Medical Genomics"},{"issue":"February (2)","key":"10.1016\/j.nbt.2013.01.005_bib0155","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/humu.21160","article-title":"Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping","volume":"31","author":"Wein","year":"2010","journal-title":"Human Mutation"},{"issue":"August (8)","key":"10.1016\/j.nbt.2013.01.005_bib0160","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ejhg.2010.4","article-title":"Therapeutic exon skipping for dysferlinopathies?","volume":"18","author":"Aartsma-Rus","year":"2010","journal-title":"European Journal of Human Genetics"},{"issue":"9","key":"10.1016\/j.nbt.2013.01.005_bib0165","doi-asserted-by":"crossref","first-page":"e24308","DOI":"10.1371\/journal.pone.0024308","article-title":"Targeting several CAG expansion diseases by a single antisense oligonucleotide","volume":"6","author":"Evers","year":"2011","journal-title":"PLoS One"},{"issue":"January (1)","key":"10.1016\/j.nbt.2013.01.005_bib0170","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nmd.2010.09.012","article-title":"The risks of therapeutic misconception and individual patient (n=1) trials in rare diseases such as Duchenne dystrophy","volume":"21","author":"Aartsma-Rus","year":"2011","journal-title":"Neuromuscular Disorders"},{"issue":"September (7414)","key":"10.1016\/j.nbt.2013.01.005_bib0175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature11247","article-title":"An integrated encyclopedia of DNA elements in the human genome","volume":"489","author":"ENCODE Project Consortium","year":"2012","journal-title":"Nature"},{"issue":"September (7414)","key":"10.1016\/j.nbt.2013.01.005_bib0180","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature11245","article-title":"Architecture of the human regulatory network derived from ENCODE data","volume":"489","author":"Gerstein","year":"2012","journal-title":"Nature"},{"issue":"September (9)","key":"10.1016\/j.nbt.2013.01.005_bib0185","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1101\/gr.134445.111","article-title":"Deep sequencing of subcellular RNA fractions shows splicing to be predominantly co-transcriptional in the human genome but inefficient for lncRNAs","volume":"22","author":"Tilgner","year":"2012","journal-title":"Genome Research"}],"container-title":["New Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871678413000083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871678413000083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:52:59Z","timestamp":1761731579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871678413000083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S1871678413000083"],"URL":"https:\/\/doi.org\/10.1016\/j.nbt.2013.01.005","relation":{},"ISSN":["1871-6784"],"issn-type":[{"value":"1871-6784","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in therapeutic RNA-targeting","name":"articletitle","label":"Article Title"},{"value":"New Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbt.2013.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}